CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa
Open Access
- 13 October 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 31, 101134
Abstract
No abstract availableKeywords
Funding Information
- University College Dublin
- Albert-Ludwigs-Universität Freiburg
- Central People's Government of the People's Republic of China Scholarship Programme (CSC202008300001)
- Science Foundation Ireland (19/FFP/6522)
This publication has 55 references indexed in Scilit:
- Genome engineering using the CRISPR-Cas9 systemNature Protocols, 2013
- TALEN-based Gene Correction for Epidermolysis BullosaMolecular Therapy, 2013
- Recessive dystrophic epidermolysis bullosa: the origin of the c.6527insC mutation in the Spanish populationBritish Journal of Dermatology, 2012
- siRNA-Mediated Allele-Specific Inhibition of Mutant Type VII Collagen in Dominant Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2012
- Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary VectorsHuman Gene Therapy, 2011
- The influence of innate and pre‐existing immunity on adenovirus therapyJournal of Cellular Biochemistry, 2009
- Parallel Synthesis and Biophysical Characterization of a Degradable Polymer Library for Gene DeliveryJournal of the American Chemical Society, 2003
- Development of spliceosome‐mediated RNA trans‐splicing (SMaRT™) for the correction of inherited skin diseasesExperimental Dermatology, 2003
- Development and Characterization of A Recombinant Truncated Type VII Collagen “Minigene”Journal of Biological Chemistry, 2000
- Gene gun and other non-viral approaches for cancer gene therapyNature Medicine, 1995